Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor
ConclusionsThe exceptional treatment response of this patient suggests that NTRK fusions are true drivers of the disease. Thus, all patients should be evaluated for NTRK fusions using sensitive methodologies and treatment with TRK fusion-protein inhibitors should be considered in patients who are not candidates for oncologic resection. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - August 5, 2020 Category: Cancer & Oncology Source Type: research
A case report of Kaposiform haemangioendothelioma; response with propranolol and steroids
ConclusionsThese cases are often misdiagnosed and despite a delay in diagnosis have good outcomes with appropriate multimodality management. This case highlights the unique and typical characteristics of kaposiform haemangioendothelioma. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 29, 2020 Category: Cancer & Oncology Source Type: research
Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk
ConclusionIn patients with localized STS > 5 cm, the high-grade subset had a distant control benefit with the addition of chemotherapy, leading to improved progression free survival. This is more pronounced with the use of MAI and should be considered in patients eligible for this regimen. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 8, 2020 Category: Cancer & Oncology Source Type: research
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
ConclusionsUndifferentiated pleomorphic sarcoma is an immunologically active subtype of soft tissue sarcoma, which is particularly amenable to immune checkpoint inhibitors. Pazopanib with immune checkpoint inhibitors is a well-tolerated, yet hitherto underexplored combination that may offer significant clinical benefit in advanced sarcomas —this finding warrants further evaluation in clinical trials. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 8, 2020 Category: Cancer & Oncology Source Type: research
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
ConclusionsOur results are in keeping with the phase III study findings: response rate, PFS and OS were similar to those reported in the phase III ANNOUNCE trial. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - May 5, 2020 Category: Cancer & Oncology Source Type: research
Evaluation of the accuracy of algorithms to identify soft tissue sarcoma (STS) in administrative claims
ConclusionsThe algorithms tested in this study sample did not achieve sufficient performance and suggest the ability to accurately identify the STS population in administrative data is problematic. Difficulties are likely due to the origin of STS in a variety of locations, the non-specific symptoms of STS, and the common diagnostic tests recommended to diagnose the disease. Future research applying machine learning to examine timing and patterns of variables that comprise the diagnostic process may further investigate the ability to accurately identify STS cases in claims databases. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - May 4, 2020 Category: Cancer & Oncology Source Type: research
The anti-neoplastic effect of doxycycline in osteosarcoma as a metalloproteinase (MMP) inhibitor: a systematic review
ConclusionDoxycycline remains a promising chemotherapeutic agent against osteosarcoma via MMP inhibition, showing the need for further in vivo and clinical trials to be carried out in the future. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - April 29, 2020 Category: Cancer & Oncology Source Type: research
Dedifferentiated soft tissue leiomyosarcoma with heterologous osteosarcoma component: case report and review of the literature
We report the case of a 65-year-old male patient who, after initial inadequate surgery of a tumor of the left forearm, developed local recurrence that was treated with neoadjuvant chemotherapy, surgery and postoperative radiation therapy. Histologically the tumor showed an abrupt separation of two different patterns. One component consisted of interlacing fascicles of spindle cells with cigar-shaped nuclei strongly positive for smooth muscle actin, desmin and H-caldesmon. The other component consisted of a high-grade pleomorphic sarcoma with osteoid and chondroid matrix production, which positive for SATB2. Thus, a final d...
Source: Clinical Sarcoma Research - April 4, 2020 Category: Cancer & Oncology Source Type: research
The immune microenvironment of uterine adenosarcomas
ConclusionsIn conclusion, this is the first report characterizing the presence of immune infiltrate and PD-1/PD-L1 expression in UA. CD3+ CD8+ T-cells density may be prognostic. The immune-responsiveness of UA needs to be further investigated in a larger study. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - March 27, 2020 Category: Cancer & Oncology Source Type: research
Accurate 3-gene-signature for early diagnosis of liposarcoma progression
ConclusionsThe identified metabolic signature allows highly accurate differential diagnosis between WD- and DDLPS even in samples containing lipid droplets, a marker of differentiation, which makes it very suitable for the use on biopsies. In respect to the pathogenesis of the disease, our results give a new insight into possible molecular mechanisms involved and support the recent observation that deletion ofPNPLA2 is a novel factor in liposarcoma progression. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - March 4, 2020 Category: Cancer & Oncology Source Type: research
Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells
ConclusionOur results demonstrate that one can use lysates from allogeneic melanoma cell lines as a source of CTA for DC load during the production of anticancer vaccines for the STBS treatment. Patterns of CTA expression should be evaluated as biomarkers of response in prospective clinical trials. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - February 3, 2020 Category: Cancer & Oncology Source Type: research
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors
ConclusionsA simple form on the long-term consequences of sarcoma treatment achieved a high response rate, was feasible to use in an outpatient clinic and facilitated communication on these issues. Fatigue was the most frequent topic raised and it was raised significantly more often in patients who had undergone chemotherapy. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - January 15, 2020 Category: Cancer & Oncology Source Type: research
Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre
ConclusionAlthough PD was the main reason for discontinuing treatment, toxicity management and dosing of regorafenib remains critical. Median duration of treatment was longer compared to previous studies suggesting a durable clinical benefit with regorafenib with rigorous toxicity management. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - January 3, 2020 Category: Cancer & Oncology Source Type: research
A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis
ConclusionOur clinico-genomic profiling of STS shows thatCDKN2A deletion was the most prevalent DNA copy number aberration and was associated with poor prognosis. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - September 10, 2019 Category: Cancer & Oncology Source Type: research
The challenge of sarcomas: the patient advocacy group perspective
ConclusionsAcross many of the challenges which I identify good progress is being made. The importance of the partnership with the professional specialists in treating sarcoma cannot be emphasised too strongly and the leadership of key people, whether patient advocates or professionals, is acknowledged. There are challenges indicated which have yet to be properly addressed. Inevitably some of them have characteristics which make them especially problematic and they tend to drop lower on everyone ’s agendas. This does not mean we should forget them. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 16, 2019 Category: Cancer & Oncology Source Type: research
